Table 1 Reported cases with t(7;21)(p22;q22)
From: Acute myeloid leukemia with t(7;21)(p22;q22) and 5q deletion: a case report and literature review
Report | Case | Diagnosis/Subtype | Age/Sex | Flow aberrancies | Induction regimen | Remission post-induction | 5q abnormalities | Outcome |
|---|---|---|---|---|---|---|---|---|
AML, NOS | ||||||||
Index case | 1 | Monocytic | 56 yo, F | CD7, CD56 | Cytarabine/Idarubicin “7+3” | Yes | Yes | CR 51 days s/p induction. Completed consolidation and recently underwent unrelated SCT |
Paulsson, et al. [8] | 2 | Minimal differentiation | 7 yo, M | Partial CD56 | NOPHO-AML-93 protocol | No | Yes (at relapse) | Relapse at 5 years with successful re-induction |
Foster, et al. [9] | 3 | Monoblastic/Monocytic | 68 yo, M | NA | MidAC | No | Dead at 5 years from unrelated illness | |
Giguère, et al. [2] | 4 | Without maturation | 32 yo, M | CD7, CD56 | Cytarabine/Daunorubicin | NA | Yes | Died of fungal infection within months of dx |
Jeandidier, et al. [10] | 5 | Myelomonocytic vs. Monblastic/Monocytic | 54 yo, M | CD2, CD7, CD22, CD56 | GOELAMS | No | Yes | Relapse at 23 months, DOD |
6 | Monoblastic/Monocytic | 33 yo, M | CD7, CD56 | SHG AML96 | No | Yes | CR after salvage chemo and allogenic transplant, alive at 36 months | |
7 | Myelomonocytic | 39 yo, M | CD22, CD56 | Cytarabine/Idarubicin | No | Yes | Partial response to salvage chemo, dead of bacterial sepsis within months of dx | |
Gindina, et al. [12] | 8 | Myelomonocytic | 13 yo, M | CD7, CD56, CD71 | AIE/HAM | No | Yes | Remission after consolidation chemo, No long-term survival data reported |
Panagopoulos, et al. [11] | 9 | Without maturation | 52 yo, F | CD7, CD56 | “Standard induction” | NA | Yes | In remission at nine months post dx, no long-term survival data reported |
MDS | ||||||||
Foster, et al. [9] | 10 | RAEB-2 (17% blasts) | 68 yo, F | NA | Mylotarg, Daunorubici, Clofarabine | Yes | No | Remained in remission post maintenance chemotherapy |